Marquette Asset Management LLC bought a new position in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 31,083 shares of the company’s stock, valued at approximately $132,000. Marquette Asset Management LLC owned 0.09% of Silverback Therapeutics at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Wasatch Advisors Inc. lifted its position in shares of Silverback Therapeutics by 67.7% during the first quarter. Wasatch Advisors Inc. now owns 2,974,228 shares of the company’s stock worth $10,440,000 after purchasing an additional 1,200,538 shares in the last quarter. Nextech Invest AG acquired a new stake in shares of Silverback Therapeutics during the fourth quarter worth about $12,721,000. BlackRock Inc. lifted its position in shares of Silverback Therapeutics by 1.8% during the first quarter. BlackRock Inc. now owns 1,607,500 shares of the company’s stock worth $5,642,000 after purchasing an additional 28,213 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Silverback Therapeutics by 82.2% during the first quarter. Renaissance Technologies LLC now owns 670,542 shares of the company’s stock worth $2,354,000 after purchasing an additional 302,542 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in Silverback Therapeutics by 16.1% in the fourth quarter. Woodline Partners LP now owns 493,895 shares of the company’s stock valued at $3,289,000 after acquiring an additional 68,634 shares in the last quarter. Hedge funds and other institutional investors own 74.89% of the company’s stock.
Silverback Therapeutics Trading Down 1.3 %
NASDAQ:SBTX traded down $0.06 during mid-day trading on Friday, hitting $4.66. The stock had a trading volume of 371,711 shares, compared to its average volume of 363,724. The stock has a 50-day simple moving average of $5.00 and a two-hundred day simple moving average of $4.12. The company has a market capitalization of $165.31 million, a PE ratio of -1.84 and a beta of 0.47. Silverback Therapeutics, Inc. has a twelve month low of $2.80 and a twelve month high of $11.85.
Silverback Therapeutics Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.